GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) » Definitions » GF Score

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) GF Score : 42/100 (As of Jun. 10, 2024)


View and export this data going back to 2016. Start your Free Trial

What is ExpreS2ion Biotech Holding AB GF Score?

ExpreS2ion Biotech Holding AB has the GF Score of 42, which implies that the company might have Worst future performance potential, or not enough data.

The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.

GF Score takes following five key aspects into consideration:

1. Financial Strength : 6/10
2. Profitability Rank : 2/10
3. Growth Rank : 2/10
4. GF Value Rank : 4/10
5. Momentum Rank : 0/10

Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.

Based on research and backtesting result, GuruFocus believes ExpreS2ion Biotech Holding AB might have Worst future performance potential, or not enough data.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Competitive Comparison of ExpreS2ion Biotech Holding AB's GF Score

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ExpreS2ion Biotech Holding AB's GF Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's GF Score distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's GF Score falls into.



ExpreS2ion Biotech Holding AB  (OSTO:EXPRS2) GF Score Explanation

Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:

GF Score Performance Potential and All-in-One Screener Examples (1)
91 - 100Highest outperformance potential
81 - 90Good outperformance potential
71 - 80Likely to have average performance
51 - 70Poor future performance potential
0 - 50Worst future performance potential, or not enough data

(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.


ExpreS2ion Biotech Holding AB GF Score Related Terms

Thank you for viewing the detailed overview of ExpreS2ion Biotech Holding AB's GF Score provided by GuruFocus.com. Please click on the following links to see related term pages.


ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Business Description

Traded in Other Exchanges
Address
c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, S-252 25
ExpreS2ion Biotech Holding AB has developed a technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. The company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with research institutions and companies.

ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Headlines

No Headlines